Ann Diagn Pathol

1. YUGUCHI S, Okubo Y, Kasajima R, Nakaigawa N, et al
   Determinants of nucleic acid quality in formalin-fixed paraffin-embedded bladder urothelial carcinoma specimens: effects of specimen type, fixation conditions, and storage time.
   Ann Diagn Pathol. 2026;85:152681.
   

   >> Share

   
   

   
   Ann Med Surg (Lond)

2. SARFRAZ M, Qureshi E, Irfan O, Rashid A, et al
   Asymptomatic bilateral renal granulomas following intravesical BCG immunotherapy for bladder cancer: a case report.
   Ann Med Surg (Lond). 2026;88:5962-5965.
   

   >> Share

   
   

   
   ANZ J Surg

3. EATON D, Kerdemelidis M, Losco G, Mark S, et al
   Cxbladder Triage in Haematuria Assessment Reduces Time From Referral to Specialist Assessment and Bladder Cancer Treatment and Improves Equity for Maori.
   ANZ J Surg. 2026 Sep 7. doi: 10.1111/ans.70960.
   

   >> Share

   
   

   
   Arch Ital Urol Androl

4. MITRAKAS L, Zisopoulos A, Dimitropoulos K, Siafakas S, et al
   Introducing "HEDGE": sequential intravesical gemcitabine-based thermochemotherapy (HIVEC) plus docetaxel as a potential novel bladder-sparing strategy for BCG-unresponsive non-muscle-invasive bladder cancer.
   Arch Ital Urol Androl. 2026 Sep 9:15738. doi: 10.4081/aiua.2026.15738.
   

   >> Share

   
   

   
   Asia Pac J Clin Oncol

5. NAKAGAWA R, Naito R, Izumi K, Inaba T, et al
   Real-World Efficacy of Postoperative Adjuvant Nivolumab in High-Risk Urothelial Carcinoma: A Retrospective Comparative Study in an Asian Population.
   Asia Pac J Clin Oncol. 2026;22:685-691.
   

   >> Share

   
   
6. ISMAIL FB, Wahid MIA, Thiagarajan M, Tan AL, et al
   Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Real-World Results From an Early Access Program in Malaysia.
   Asia Pac J Clin Oncol. 2026;22:744-748.
   

   >> Share

   
   

   
   BJU Int

7. GABRIEL PE, Zhu A, Karim CG, Eraky A, et al
   Outcomes of maintenance BCG versus gemcitabine/docetaxel following BCG induction in NMIBC.
   BJU Int. 2026;138:640-649.
   

   >> Share

   
   
8. CONTIERI R, van Rhijn BWG, Cathomas R, Lorch A, et al
   Response evaluation of neoadjuvant therapy in MIBC: clinical trial-derived evidence to guide practice.
   BJU Int. 2026;138:558-564.
   

   >> Share

   
   
9. CONNOR MJ, Gopalakrishnan A, Mayor N, Bolton E, et al
   Immediate intraoperative detrusor muscle status at primary transurethral resection of bladder tumour: a prospective, blinded, paired cohort, feasibility study using fluorescence confocal microscopy (IB1-LaserComplete study).
   BJU Int. 2026;138:705-713.
   

   >> Share

   
   
10. HURLE R, Contieri R, Sormani F, Lazzeri M, et al
    Quality of life in patients on active surveillance for bladder cancer.
    BJU Int. 2026 Sep 9. doi: 10.1111/bju.70449.
    

    >> Share

    
    

    
    BMJ Case Rep

11. AHMAD B, Malik A, Brown P, Kumar A, et al
    Vesicocutaneous fistula secondary to invasive bladder squamous cell carcinoma: an unusual initial presentation.
    BMJ Case Rep. 2026;19:e269395.
    

    >> Share

    
    

    
    Cancer Cytopathol

12. MERCADER C, Ingelmo-Torres M, Roldan FL, Figueras M, et al
    Refining risk stratification after indeterminate urinary cytology: Evidence from Bladder EpiCheck.
    Cancer Cytopathol. 2026;134:e70141.
    

    >> Share

    
    

    
    Cancer Med

13. XU JL, Fan CQ, Peng YQ, Yang XT, et al
    Factors Associated With Self-Perceived Burden and Its Relationship With Quality of Life Among Patients With Bladder Cancer Undergoing Ileal Conduit Urinary Diversion: A Cross-Sectional Study.
    Cancer Med. 2026;15:e72253.
    

    >> Share

    
    

    
    Cell Signal

14. WANG L, Yang J, Wan S, Li K, et al
    PRDX1 facilitates USP7-dependent stabilization of SCD1 and promotes bladder cancer progression.
    Cell Signal. 2026;149:112882.
    

    >> Share

    
    

    
    Chin J Cancer Res

15. PAN S, Xu W, Xiang Y, Huang M, et al
    Overcoming barriers to bladder preservation: Emerging intravesical therapies for high-risk non-muscle-invasive bladder cancer.
    Chin J Cancer Res. 2026;38:411-430.
    

    >> Share

    
    

    
    Clin Exp Med

16. WANG H, Liu H, Li Q, Sun F, et al
    Exploring the mechanism by which triphenyl phosphate promotes malignant phenotypes in bladder and kidney cancer through MMP9 based on bioinformatics analysis and experimental validation.
    Clin Exp Med. 2026;26:324.
    

    >> Share

    
    

    
    Curr Opin Pediatr

17. GABRIELSON AT, Grabski DF, Lautz TB, Gong EM, et al
    Modern management and multidisciplinary care of bladder prostate rhabdomyosarcoma.
    Curr Opin Pediatr. 2026;38:531-537.
    

    >> Share

    
    

    
    Environ Epidemiol

18. KAMENETSKY ME, Koutros S, Spaur M, Kim SD, et al
    Associations between a mixture of trace elements and bladder cancer occurrence: A study of possible reverse causation.
    Environ Epidemiol. 2026;10:e525.
    

    >> Share

    
    

    
    Eur J Cancer

19. SONG B, Maurya H, Xia T, Tokuyama N, et al
    A stromal-immune computational pathology signature for prognosis and immune checkpoint inhibitor response in localized, locally advanced and metastatic urothelial carcinoma: A multicenter retrospective study.
    Eur J Cancer. 2026;246:116979.
    

    >> Share

    
    

    
    Eur Urol Oncol

20. NOSSING C, Prantl I, Grausenburger R, Ertl IE, et al
    Gemcitabine-Cisplatin Chemotherapy Induces Nectin-4 Downregulation and Enfortumab Vedotin Resistance in Bladder Cancer.
    Eur Urol Oncol. 2026 Sep 8:S2588-9311(26)00232-4. doi: 10.1016/j.euo.2026.
    

    >> Share

    
    

    
    Exp Mol Pathol

21. AHMADI P, Deyhimfar R, Haghani I, Mohammadi A, et al
    Corrigendum to "Citalopram enhances cisplatin-induced cytotoxicity in T24 bladder cancer cells: An in vitro study" [Exp. Mol. Pathol. 147 (2026) 105056].
    Exp Mol Pathol. 2026 Sep 11:105074. doi: 10.1016/j.yexmp.2026.105074.
    

    >> Share

    
    

    
    Fr J Urol

22. DUQUESNE I, Chakra MA, de la Taille A, O'Donnell MA, et al
    Risk Stratification in Non-Muscle-Invasive Bladder Cancer in the Era of Expanding Therapeutic Options: Are Current Classifications Still Adequate?
    Fr J Urol. 2026 Sep 9:103200. doi: 10.1016/j.fjurol.2026.103200.
    

    >> Share

    
    

    
    Front Cell Dev Biol

23. HE Y, Lu W, Ju G, Chen L, et al
    Single-cell transcriptomics deciphers cancer-associated fibroblast heterogeneity and immune regulatory mechanisms in the bladder cancer tumor microenvironment.
    Front Cell Dev Biol. 2026;14:1889050.
    

    >> Share

    
    

    
    Front Med (Lausanne)

24. HUANG F, Chen C, Mao Y, Lin T, et al
    Prognostic effect of the preoperative albumin-to-globulin ratio bladder cancer: a meta-analysis.
    Front Med (Lausanne). 2026;13:1848522.
    

    >> Share

    
    

    
    Gan To Kagaku Ryoho

25. KAWAHARA T, Nishiyama H
    [Evolving Role of Perioperative Immune Checkpoint Inhibitors in Muscle-Invasive Bladder Cancer].
    Gan To Kagaku Ryoho. 2026;53:507-511.
    

    >> Share

    
    

    
    Int J Clin Oncol

26. MATSUMURA N
    PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; sevabertinib for lung cancer, gemcitabine intravesical system and durvalumab for bladder cancer, azacitidine for leukemia, cemiplimab for skin can
    Int J Clin Oncol. 2026 Sep 6. doi: 10.1007/s10147-026-03190.
    

    >> Share

    
    

    
    Int J Med Robot

27. XU J, Huang Q, Deng G, Ye Y, et al
    A Novel Technique of Traction Pre-Bladder Suturing in Single-Position Robot-Assisted Nephroureterectomy: Simplifying the Management of the Intramural Ureter.
    Int J Med Robot. 2026;22:e70230.
    

    >> Share

    
    

    
    Int J Urol

28. YANAGISAWA T, Matsukawa A, Iwatani K, Hayashida Y, et al
    Perioperative Safety and Long-Term Oncological Outcomes of En Bloc Resection of Bladder Tumor: A Multicenter Real-World Study of 668 Patients.
    Int J Urol. 2026;33:e70634.
    

    >> Share

    
    

    
    iScience

29. ZHOU R, Zhang W, Xia M, Zhang K, et al
    Pentachlorophenol enhances bladder cancer cell invasion through altered protein stability.
    iScience. 2026;29:117357.
    

    >> Share

    
    

    
    IUBMB Life

30. CAMARGO JA, Lee MC, Souza MM, Silva LPD, et al
    MMP9 Knockout by CRISPR-Cas9 Reduces Bladder Cancer Malignancy But Does Not Synergize With BCG and Anti-PD-L1 in an Orthotopic Mouse Model.
    IUBMB Life. 2026;78:e70130.
    

    >> Share

    
    

    
    J Cancer Allied Spec

31. RANJHA FR, Rashid A, Adnan A, Kashif M, et al
    Treatment Patterns and Long-Term Survival Outcomes in Muscle-Invasive Bladder Cancer: A Decade-Long Single-Institution Retrospective Cohort Study.
    J Cancer Allied Spec. 2026;12:122-128.
    

    >> Share

    
    

    
    J Racial Ethn Health Disparities

32. DE ANGELIS M, Siech C, Jannello LMI, Di Bello F, et al
    Does Race/Ethnicity Affect Secondary Bladder and Rectal Cancer Rates After Prostate Cancer Radiation? Results from a Population-Based Study.
    J Racial Ethn Health Disparities. 2026;13:3888-3896.
    

    >> Share

    
    

    
    J Surg Oncol

33. OKUMURA G, Yajima S, Ikezoe E, Gozu S, et al
    Treatment Selection and Survival In Muscle-Invasive Bladder Cancer: Real-World Data on the Impact of Geriatric-8 Screening.
    J Surg Oncol. 2026 Sep 6. doi: 10.1002/jso.70399.
    

    >> Share

    
    

    
    J Urol

34. JAYRAM G, Shore ND, Tyson M, Pieczonka C, et al
    PD09-07 Durvalumab in Combination with Bacillus Calmette-Guerin for Bacillus Calmette-Guerin-Naive, High-Risk Non-Muscle-Invasive Bladder Cancer: Primary Results from a US-Based, Phase IIIB, Open-Label, Single-Arm, Multicenter Study (PATAPSCO): Erratu
    J Urol. 2026;216:606.
    

    >> Share

    
    
35. SHORE ND, Nishiyama H, Redorta JP, Krawczynski M, et al
    Durvalumab in Combination with Bacillus Calmette-Guerin Induction and Maintenance Therapy for Bacillus Calmette-Guerin-Naive, High-Risk Non-muscle-Invasive Bladder Cancer: Expanded Efficacy and Safety Analyses from POTOMAC: Erratum.
    J Urol. 2026;216:607.
    

    >> Share

    
    
36. GARMAN TS, Lokeshwar S, Campbell J, Su ZT, et al
    Phase 2 Trial of Intravesical Gemcitabine and Docetaxel as First-Line Treatment of Bacillus Calmette-Guerin?Naive Nonmuscle-Invasive Urothelial Carcinoma: Updated, 3-Year Outcomes.
    J Urol. 2026;216:540-550.
    

    >> Share

    
    

    
    Jpn J Clin Oncol

37. KANAGAWA T, Yonese I, Nakamura T, Shimizu M, et al
    Adverse impact of bladder biopsy on the rate of intravesical recurrences following radical nephroureterectomy for upper tract urothelial carcinoma.
    Jpn J Clin Oncol. 2026;56:1103-1110.
    

    >> Share

    
    

    
    Mater Today Bio

38. ZHANG B, Zhu J, Hong Z, Wang Y, et al
    An engineered bacteria-chitosan hybrid robot for lactate depletion and synergistic STING activation to potentiate bladder cancer immunotherapy.
    Mater Today Bio. 2026;40:103593.
    

    >> Share

    
    

    
    Med Oncol

39. YI H, Han Y, Wang X, Li Q, et al
    IGF2BP3 enhances paclitaxel resistance in bladder urothelial carcinoma by recognizing m(6)A-modified CENPA mRNA.
    Med Oncol. 2026;43:278.
    

    >> Share

    
    

    
    Mol Biol Rep

40. KAWASAKI JAI, de Souza AP, Pontes JPR, Serpeloni JM, et al
    Impact of BCL-2 rs2279115 and rs3943258 variants on protein expression and clinical outcome of urothelial bladder carcinoma.
    Mol Biol Rep. 2026;53:1544.
    

    >> Share

    
    

    
    Mol Oncol

41. RIBEIRO-PEREIRA R, Teixeira-Marques A, Freitas R, Carvalho JA, et al
    Predictive and prognostic biomarkers of Bacillus Calmette-Guerin therapy failure in bladder cancer patients: A systematic review.
    Mol Oncol. 2026 Sep 7:10.1002/1878-0261.70329. doi: 10.1002/1878-0261.70329.
    

    >> Share

    
    
42. SALHI Y, Makrodimitris S, van Wilpe S, Te Paske I, et al
    Longitudinal genome-wide aneuploidy measurements in circulating cell-free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer.
    Mol Oncol. 2026;20:2175-2187.
    

    >> Share

    
    

    
    Mol Pharm

43. AZIZ MN, Wang T, Lang J, Glover M, et al
    Payload-Free [89Zr]Zr-DFO*-sq-Enfortumab ImmunoPET for Imaging Nectin-4 Expression in Bladder Cancer.
    Mol Pharm. 2026;23:4758-4769.
    

    >> Share

    
    

    
    Nanomedicine (Lond)

44. MUKHERJEE S, Karati D, Sarkar S, Ash D, et al
    CRISPR-Cas9?based lipid nanocarriers for advanced therapy of urinary bladder cancer.
    Nanomedicine (Lond). 2026 Sep 10:1-11. doi: 10.1080/17435889.2026.2732014.
    

    >> Share

    
    

    
    Nat Commun

45. PROKUNINA-OLSSON L, Florez-Vargas O, Levin MG, Dutta D, et al
    Multi-population GWAS meta-analysis identifies bladder cancer susceptibility loci and highlights genetic regulation of smoking-related risk.
    Nat Commun. 2026;17:9591.
    

    >> Share

    
    
46. ZHANG Z, Han L, Jia D, Wei Y, et al
    MRICombo: a deep-learning-based framework for universal volumetric segmentation grading-staging and malignancy detection across heterogeneous MRI.
    Nat Commun. 2026;17:9715.
    

    >> Share

    
    

    
    PLoS One

47. NAUMAN RW, Greer PA, Craig AW, Cotechini T, et al
    Differential effects of BCG-Russia and BCG-TICE on trained immunity: Potential implications for bladder cancer immunotherapy.
    PLoS One. 2026;21:e0357950.
    

    >> Share

    
    

    
    Support Care Cancer

48. PEAT N, Jones GD, Veal I, Kinsella N, et al
    Physical activity in advanced urological cancers undergoing immune checkpoint inhibitor treatment: a qualitative study exploring patient perspectives and experiences.
    Support Care Cancer. 2026;34:963.
    

    >> Share

    
    

    
    Transl Androl Urol

49. HE J, Zhao J, Luo Y, Li M, et al
    Integrated bioinformatics analyses for GSDMB in carcinogenesis and progression of bladder cancer.
    Transl Androl Urol. 2026;15:295.
    

    >> Share

    
    
50. GILFRICH C, Kravchuk A, Rinderknecht E, Haas M, et al
    Beyond staging: toward a layered risk architecture after radical cystectomy for bladder cancer.
    Transl Androl Urol. 2026;15:260.
    

    >> Share

    
    
51. ZHOU J, Geng J, Qiu H, Guo J, et al
    Multi-omics integration identifies HSPA4 as a therapeutic target and reveals DON-induced endoplasmic reticulum stress in bladder cancer.
    Transl Androl Urol. 2026;15:262.
    

    >> Share

    
    
52. CAO J, Yang J, Shang W, Tan H, et al
    Integrated transcriptome analysis and machine learning to construct a homeostatic model of acetylation for bladder cancer and validate the key gene CES1.
    Transl Androl Urol. 2026;15:271.
    

    >> Share

    
    

    
    Transl Cancer Res

53. 
    Retraction: Long non-coding RNA MEG3 functions as a competing endogenous RNA of miR-93 to regulate bladder cancer progression via PI3K/AKT/mTOR pathway.
    Transl Cancer Res. 2026;15:675.
    

    >> Share

    
    

    
    Urol Oncol

54. NOZAKI M, Nakagawa R, Kadono Y, Koketsu Y, et al
    Incidental bladder cancer detected by routine cystoscopy before robot-assisted radical prostatectomy: A multicenter retrospective study.
    Urol Oncol. 2026 Sep 11:S1078-1439(26)00709.
    

    >> Share

    
    
55. WANG J
    Calendar-time bias in a TriNetX study of GLP-1 receptor agonists, SGLT2 inhibitors and bladder cancer survival.
    Urol Oncol. 2026 Sep 10:S1078-1439(26)00714.
    

    >> Share

    
    
56. LI X, Su M, Luo J, Han D, et al
    FOXD1 upregulates DARS2-mediated glycolysis to drive cisplatin resistance in bladder cancer.
    Urol Oncol. 2026 Sep 5:S1078-1439(26)00619-8. doi: 10.1016/j.urolonc.2026.
    

    >> Share

    
    
57. CORVINO R, Basile G, Santarelli V, Asero V, et al
    Perioperative and survival outcomes of synchronous vs. metachronous upper tract urothelial carcinoma among bladder cancer patients treated with radical cystectomy and nephroureterectomy: Results from an International Multicenter Collaborative Study-On
    Urol Oncol. 2026 Sep 5:S1078-1439(26)00699-X. doi: 10.1016/j.urolonc.2026.
    

    >> Share

    
    

    
    Urologie

58. GAKIS G, Vom Dorp F
    [Immune checkpoint inhibition plus Bacillus Calmette-Guerin (BCG) therapy in BCG-naive high-risk non-muscle-invasive bladder cancer: a critical review in the context of current evidence].
    Urologie. 2026 Sep 4. doi: 10.1007/s00120-026-02922.
    

    >> Share

    
    

    
    World J Urol

59. MATSUSHITA Y, Taguchi S, Naiki T, Ishikawa G, et al
    Six-factor-based stratification system for enfortumab vedotin monotherapy in pre-treated patients with metastatic or locally advanced urothelial carcinoma.
    World J Urol. 2026;44:657.
    

    >> Share

    
    
60. ARYA R, Mohapatra AK
    Comment on "A molecular landscape tracking the progression of non-muscle invasive bladder cancer".
    World J Urol. 2026;44:645.
    

    >> Share

    
    

    
    Zhong Nan Da Xue Xue Bao Yi Xue Ban

61. LI J, Xue Y, Guo Z, Ye S, et al
    [Advances in intravesical therapy for non-muscle-invasive bladder cancer].
    Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2026;51:1288-1296.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share